Roivant Sciences has announced that it has entered into collaboration with Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) to facilitate the out-licensing of investigational medicines.

Under the terms of the agreement, Roivant will have the option to obtain exclusive licenses for certain development programs from Daiichi Sankyo on pre-specified terms contingent on phase of development.

Dr. Mayukh Sukhatme, President of Roivant Pharma said, “It has been an honor and a pleasure for us to work with the entire Daiichi Sankyo team in the course of creating this partnership. I hope this can be a model for platform collaborations between Roivant and other innovative biopharmaceutical companies in the future. We look forward to accelerating the development of promising medicines from the impressive R&D engine at Daiichi Sankyo in the months and years ahead.”

Daiichi Sankyo has a wide range of compounds in development. Medicines that Roivant opts to license will be developed by new subsidiary companies within the Roivant family.